Mounjaro Tirzepatide 7.5mg
Mounjaro Tirzepatide 7.5mg
Ships From 🇨🇳 China, 12-15 Business Days.
Note: Separate shipping fee per warehouse.
Mounjaro® (Tirzepatide) 7.5 mg is a prescription medication containing tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Developed by Eli Lilly and Company, Mounjaro is indicated for improving glycemic control in adults with type 2 diabetes mellitus and, in some regions, may also have additional approved indications depending on local regulatory authorities.
The 7.5 mg strength is typically used as part of the recommended dose-escalation schedule following the 5 mg dose, allowing treatment to be individualized under the supervision of a qualified healthcare provider.
Benefits
- Dual GIP and GLP-1 receptor agonist
- Once-weekly subcutaneous administration
- Intermediate dose in the recommended dose-escalation schedule
- Supports blood glucose management in adults with type 2 diabetes (as approved)
- Convenient carton containing 4 prefilled single-dose injection pens
- Manufactured to strict pharmaceutical quality standards
Common Clinical Use
- Type 2 diabetes mellitus management
- Dose escalation following the 5 mg maintenance dose
- Physician-supervised metabolic therapy
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Mounjaro® (Tirzepatide) |
| Strength | 7.5 mg/0.5 mL |
| Packaging | 4 Prefilled Single-Dose Injection Pens |
| Dosage Form | Solution for Injection |
| Route of Administration | Subcutaneous Injection |
| Active Ingredient | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
Storage
Store refrigerated at 2°C–8°C. Do not freeze. Keep the pens in their original carton to protect them from light. Follow the manufacturer's recommendations regarding room-temperature storage before use.
Important Information
Prescription medicine.
Mounjaro must be used only under the supervision of a qualified healthcare professional and in accordance with the approved prescribing information in your country. Read the accompanying patient information leaflet before use. Keep out of reach of children.